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Abstract Triple-negative breast cancers lack estrogen
receptor a (ERa), progesterone receptor, and do not over-
express human epidermal growth factor receptor 2 (Her-2).
They are neither susceptible to endocrine therapy nor to a
therapy using the anti-Her-2 antibody, trastuzumab.
Therefore, an efficient targeted therapy is warranted.
Triple-negative breast tumors frequently express mem-
brane bound estrogen receptor G-protein coupled receptor
(GPR30). As proof of principle, we analyzed the conse-
quences of a knock-down of GPR30 expression on the
growth regulation of triple-negative breast cancer cell
lines. Cells of triple-negative breast cancer cell lines were
transfected with siRNA against GPR30 or control siRNA,
and cell growth was stimulated either with 10-9 M
17b-estradiol or 10-6 M 4-hydroxytamoxifen. Cell prolif-
eration was measured using Alamar blue staining. Acti-
vation of c-Src and epidermal growth factor (EGF)-
receptor was assessed using western blot. Expression of c-
fos was quantified by reverse transcription polymerase
chain reaction. Seven days after transfection with siRNA,
GPR30 mRNA in triple-negative breast cancer cell lines
MDA-MB-435 and HCC1806 was reduced by 74 and 90%,
respectively. 10-8 M 17b-estradiol enhanced proliferation
of MDA-MB-435 to 129.6 ± 5.4% of control (p \ 0.05)
and HCC1806 to 156.9 ± 15.4% of control (p \ 0.05),
respectively. 10-6 M 4-hydroxytamoxifen increased cell
number of MDA-MB-435 to 121.0 ± 6.9% of control
(p \ 0.05) and HCC1806 to 124.5 ± 12.1% of control
(n.s.), respectively. This increased proliferation by the two
estrogenic compounds was completely prevented by
knock-down of GPR30 expression in both cell lines. In
control cells, activity of Src kinase was increased 3-fold by
estradiol and 3.8-fold using 4-hydroxytamoxifen. Trans-
activation of the EGF-receptor was similarly increased in
both cell lines by 17b-estradiol and 4-hydroxytamoxifen.
Both compounds increased c-fos expression 1.5- and
3.1-fold, respectively. Knock-down of GPR30 expression
completely abolished activation of all these signaling
pathways responsible for enhanced proliferation. A phar-
macological inhibition of GPR30 by specific small
molecular inhibitors might prove to be an appropriate tar-
geted therapy of triple-negative breast cancer in the future.
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Breast cancer is the most frequent malignancy in women.
Endocrine therapy with the anti-estrogen tamoxifen or
aromatase inhibitors achieves an overall survival of about
82% of patients after 8 years of treatment [1]. A subgroup
of tumors expressing neither ERa nor progesterone
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receptor and not overexpressing Her-2 accounting for
15–20% of all breast tumors is called triple-negative breast
cancer. These tumors, not susceptible to endocrine therapy,
are currently treated with conventional chemotherapy. The
death rate of patients with triple-negative breast cancer is
double as high as in the case of ERa-positive tumors [2].
Triple-negative breast cancers frequently carry muta-
tions of the BRCA1 gene, for this reason, they turn out to
be sensitive to platinum compounds. The combination of
platinum and the epidermal growth factor (EGF)-R anti-
body Cetuximab increased the response rate from 30 to
49% [3]. Inhibitors of poly-ADP-ribose polymerase
(PARP) were also found to be promising in triple-negative
breast cancer [4, 5].
In MDA-MB-435 and MDA-MB-231 cells, lacking
detectable expression of ERa, Tsai et al. [6] observed a rapid
phosphorylation of protein kinase Akt at Ser473 after stim-
ulation with 17b-estradiol. Adenylate cyclase activity was
increased in MCF-7 breast cancer cells by 17b-estradiol
within minutes leading to an activation of protein kinase A
[7]. An activation of the MAP-kinase extracellular signal-
regulated kinase (Erk) was also observed after short time
stimulation of MCF-7 breast cancer cells with 17b-estradiol
[8, 9]. It was assumed that an estrogen receptor resides at the
plasma membrane [10]. Finally, the G-protein coupled
receptor, GPR30, was identified to be responsible for most of
the non-genomic signaling events of 17b-estradiol [11, 12].
Binding of 17b-estradiol to GPR30 leads to a dissociation of
the heterotrimeric G-protein complex. The bc-subunit acti-
vates the tyrosine kinase Src [13]. Subsequently, EGF from
the extracellular matrix elicits the autophosphorylation of
the EGF-receptor leading to the activation of the ras-MAP-
kinase pathway [14].
GPR30 has been proposed to be an excellent new ther-
apeutic target for the treatment of triple-negative breast
cancer [15].
In addition to 17b-estradiol, selective estrogen receptor
modulator, tamoxifen, and complete ERa antagonist, ful-
vestrant, bind to GPR30 and induce adverse effects in
breast cancer cells [11].
The experiments described in this report were performed
to elucidate the role of GPR30 in the proliferative response
of triple-negative breast cancer cells to 17b-estradiol and
anti-estrogen 4-hydroxytamoxifen. For this purpose,
GPR30 expression was reduced in two triple-negative
breast cancer cell lines using specific siRNA. The conse-
quences of the knock-down of GPR30 expression were
analyzed at several points along the signaling pathway of
GPR30 after stimulation with either 17b-estradiol or
4-hydroxytamoxifen. The enhancement of proliferation of
the triple-negative cell lines by 17b-estradiol or 4-hy-




17b-Estradiol (E2), 4-hydroxytamoxifen, insulin, and
transferrin were purchased from Sigma-Aldrich (Deisen-
dorf, Germany). siRNA for GPR30 and non-specific con-
trol siRNA were obtained from SantaCruz Biotech (Santa
Cruz, CA).
Cell lines
MDA-MB-435 [16] was purchased from ATCC (Manassas,
VA) and maintained in phenol red-free DMEM (Biochrom,
Berlin, Germany) supplemented with 2 mM glutamine,
6 ng/ml insulin, 10 ng/ml transferrin, penicillin (50 U/ml),
streptomycin (50 lg/ml) from Gibco (Paisley, UK), and
5% fetal bovine serum (Biochrom, Berlin).
Breast cancer cell line HCC1806 was purchased from
ATCC (Manassas, VA). Cells were maintained in phenol
red-free MEM with Earle’s salts supplemented with 5% fetal
calf serum (FCS, Biochrom, Berlin), 2 mM glutamine, and
50 U/ml penicillin/streptomycin (Gibco, Paisley, UK).
Transfection with siRNA
4 9 105 Cells of each triple-negative breast cancer cell line
were seeded in 2 ml growth medium into 25 cm2 culture
flasks and grown to 80% confluence.
GPR30 siRNA (sc-60743) and nonspecific control
siRNA (sc-37007) from SantaCruz (Santa Cruz, CA) were
dissolved in RNAse-free water at a concentration of
10 lM. Sixteen microliters of each siRNA were diluted in
400 ll transfection medium (sc-36868). In addition, 32 ll
transfection reagent (sc-29528) was added to another
400 ll transfection medium. Equal volumes of the diluted
siRNA and transfection reagent were mixed and incubated
at room temperature for 45 min.
Growth medium was removed from the culture flasks,
and 2 ml transfection medium (sc-36868) was added to the
cells. After 10 min at 37C, transfection medium was
replaced by the mixture of siRNA and transfection reagent,
and the transfection was started. After 6 h, 2 ml of a
growth medium containing a twofold concentration of FCS
and antibiotics was added to the transfected cells. After
further 18 h, the remaining siRNA was aspirated and cells
were grown in normal culture medium until transfected
cells were used for analysis.
RT-PCRs
RNA of the transfected breast cancer cells was purified
using the RNeasy-kit (Qiagen, Hilden, Germany).
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200 ng of each RNA was transcribed using 400 U
Superscript reverse transcriptase (Invitrogen, Karlsruhe,
Germany) in the presence of 0.5 lM oligo-dT primer for
60 min at 37C. Five microliter of the resulting cDNA was
amplified with 1 U Taq polymerase (Peqlab, Erlangen,
Germany) in the presence of 200 lM dNTPs and 200 nM
of the appropriate primers.
GPR30: primer A: AGTCGGATGTGAGGTTCAG
Primer B: TCTGTGTGAGGAGTGCAAG
c-fos: primer A: GAGATGGAGATCGGTATGGT
Primer B: CAGGTCTGAATCAGTGCCTT
Optimal PCR conditions for each gene were ascertained,
guaranteeing that generation of the PCR products was in
the exponential phase. Therefore, cDNA of GPR30 was
amplified by 28 cycles and c-fos by 32 cycles. As refer-
ence, the RNA of the ribosomal protein L7 was amplified
by 20 cycles.
PCR products were separated in a 2% agarose gel (Type
IV, special high EEO, Sigma Chemicals, Steinheim, Ger-
many) in 0.59 TBE buffer at 100 V for 30 min. Gels were
stained in ethidium bromide (2 lg/ml) for 30 min and
photographed on a transilluminator using a CDS camera
(TD20, Kodak, Rochester).
Proliferation assays
The proliferation assays for 17b-estradiol and 4-hydroxy-
tamoxifen were performed in phenol red-free medium
supplemented with charcoal depleted serum (CD-FCS) as
previously described [16]. CD-FCS was prepared accord-
ing to the procedure described by Stanley et al. [17].
In brief, 2,000 cells/well were seeded in 100 ll CD-FCS
medium (10% CD-FCS) into 96-well plates. After attach-
ment of the cells, 100 ll CD-FCS medium containing
either vehicle (control) or 17b-estradiol (10-9 and 10-8 M)
or 4-hydroxytamoxifen (10-7 and 10-6 M) were added to
four replicate wells for each concentration.
Cells were grown for 7 days at 37C, 5% CO2, and
saturated humidity. Cell number was determined by a
colorimetric method using Alamar blue (Biosource,
Solingen, Germany) [16].
Proliferation assays were performed at least three times
in quadruplicates with different passages. Means and
standard deviations of the optical density (OD) of the
replicates were calculated.
Assays of GPR30 signaling
For analysis of GPR30 signal transduction pathway, 106
cells/well were plated in serum-free culture medium into
6-well plates (35 mm). Cells were serum starved for 24 h
to synchronize the 17b-estradiol-starved cells in G0-phase.
Serum starved cells were stimulated with 10-8 M
17b-estradiol or 10-6 M 4-hydroxytamoxifen for 10 or
20 min. Cells were harvested and cell pellets lysed in 100 ll
Cell lytic M (Sigma, Deisendorf, Germany), supplemented
with protease inhibitor (Sigma, Deisendorf, Germany) and
phosphatase inhibitor (Sigma, Deisendorf, Germany).
Western blots
Lysates of cells were cleared at 15,000g for 5 min, and the
protein concentration in the supernatant was determined
using the method of Bradford. 50 lg of each sample was
separated in a 7.5% polyacrylamide gel, blotted on PVDF-
membrane, and sequentially detected with rabbit-anti-
human primary antibodies: anti-phospho-Src (2113), anti-
Src (2109), anti-phospho Tyr1173EGF-receptor (324864)
from Calbiochem (Darmstadt, Germany), anti-EGF-recep-
tor antibody (2235) from Epitomics (Hamburg, Germany)
and anti-actin from Sigma Chemicals (Deisendorf, Ger-
many). After washing in TBST, blots were incubated with
a 1:20.000 dilution of horseradish peroxidase-conjugated
goat-anti-rabbit antibody (ECL, GE-Healthcare, Freiburg,
Germany). After washing, blots were incubated with a
chemoluminescence reagent and exposed to X-ray film
(BiomaxMR, Kodak, Rochester, USA). Densitometric
evaluations of the protein bands were normalized to actin.
Densitometric evaluation of PCR products
The bands of the PCR products were photographed using
a CDS camera and evaluated by the Digital science
1D-software (Kodak, Rochester, USA). Values of the
reverse transcription polymerase chain reaction (RT-PCR)
products were normalized to the ribosomal protein L7.
Statistical analysis
The data were tested for significant differences by one-way
analysis of variance followed by Student–Newman–Keuls’
test for comparison of individual groups, after a Bartlett
test had shown that variances were homogenous.
Results
Degradation of GPR30 mRNA by the treatment
with siRNA
Triple-negative breast cancer cell lines MDA-MB-435 and
HCC1806 were transfected with either non-specific siRNA
(control; -si) or with siRNA specific for GPR30 (?si).
Expression of mRNA for GPR30 was analyzed using
RT-PCR at various time points after transfection in order to
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track the time course of the decline of GPR30 mRNA
expression in both cell lines. Treatment with non-specific
siRNA did not change expression of GPR30 mRNA (data
not shown). In MDA-MB-435 cells transfected with
GPR30 siRNA, the amount of GPR30 mRNA was gradu-
ally decreasing with growing time of exposure to siRNA.
m-RNA for GPR30 was lowest 7 days after transfection
with siRNA and started to increase again on day 10 of
siRNA treatment (Fig. 1). Seven days after transfection of
MDA-MB-435 cells, expression of GPR30 mRNA was
reduced to 26%.
In HCC1806 cells, expression of GPR30 mRNA
decreased more slowly after transfection. Ten days after
transfection, the amount of GPR30 mRNA was minimal
and accounted for 10% of the expression in non-treated
HCC1806 cells. L7 expression was unaffected by the
treatment with GPR30 siRNA.
Inactivation of GPR30 slows down proliferation
of triple-negative breast cancer cells
Proliferation of triple-negative breast cancer cell lines
MDA-MB-435 and HCC1806 could be stimulated by 17b-
estradiol and 4-hydroxytamoxifen (Fig. 2a, b). To test
whether GPR30 is involved in the growth promoting effect
of these two compounds, proliferation tests were performed
with cells pretreated with siRNA against GPR30 (?si).
After treatment of MDA-MB-435 control cells (-si) with
10-8 M 17b-estradiol, the cell number increased to
129.6 ± 5.4% of control (C = 100%; p \ 0.05). The
17b-estradiol-induced increase was completely obviated by
knock-down of GPR30 (?si; p \ 0.05). After treatment of
MDA-MB-435 control cells (-si) with 10-6 M 4-hy-
droxytamoxifen, the cell number increased to
121.0 ± 6.9% of control (C = 100%; p \ 0.05). Knock-
down of GPR30 expression completely suppressed the
effect of 4-hydroxytamoxifen on proliferation of MDA-
MB-435 cells (?si; 93%; p \ 0.05) (Fig. 2a). In the
HCC1806 breast cancer cell line, treatment with 10-8 M
17b-estradiol increased the number of control cells (-si) to
156.9 ± 15.4% of control (C = 100%; p \ 0.05). This
growth stimulation was completely prevented by knock-
down of GPR30 expression (?si; 82%; p \ 0.05). After
treatment of HCC1806 control cells (-si) with 10-6 M
4-hydroxytamoxifen, the cell number increased to
124.5 ± 12.1% of control (C = 100%; n.s.). Knock-down
of GPR30 expression completely suppressed the growth
stimulation by 4-hydroxytamoxifen (?si; 97%; n.s.)
(Fig. 2b).
Fig. 1 Knock-down of GPR30 expression in triple-negative breast
cancer cell lines. MDA-MB-435 and HCC1806 were transfected with
siRNA specific for GPR30. mRNA of the cells was extracted 1, 4, 7,
and 10 days after transfection, transcribed into cDNA and amplified
by PCR using specific primers. L7, a ribosomal housekeeping gene,
was amplified to prove the presence of equal amounts of RNA in each
PCR reaction of the respective cell line. Representative results from
three independent transfections
Fig. 2 Inhibition of proliferation of triple-negative breast cancer cells
after knock-down of GPR30 expression. a MDA-MB-435, b HCC1806.
Cells transfected with non-specific siRNA (-si) or with GPR30siRNA
(?si) were grown for 7 days in culture medium supplemented with 10%
charcoal-treated FCS either in the absence or presence of 10-8 M 17b-
estradiol or 10-6 M 4-hydroxytamoxifen. Cell number was evaluated in
microwell plates by a colorimetric assay using Alamar blue. ODs
measured in the non-stimulated wells (control) were set 100%. The ODs
estimated in the stimulated wells were divided by the values of the
control well to give the relative cell number in % achieved under the
indicated conditions. Doubling times of cell lines in hormone-depleted
medium (control cells) were: MDA-MB-435: *48 h; HCC1806:
*36 h. Data are mean values and SE of three independent experiments
with four replicates. a p \ 0.05 versus control, b p \ 0.05 versus -si
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Impact of GPR30 knock-down on signal transduction
of GPR30
Stimulation of GPR30 by 17b-estradiol is known to
increase activity of the non-receptor tyrosine kinase
Src. Treatment of MDA-MB-435 cells with 10-9 M
17b-estradiol for 10 min clearly increased phosphorylation
of Src at Tyr416 about threefold (Fig. 3, upper panel, lane 2).
In MDA-MB-435 cells transfected for 7 days with GPR30
siRNA, the increase of Src phosphorylation by 17b-estradiol
was completely abolished (lane 3). After treatment with 10-6
M 4-hydroxytamoxifen for 10 min phosphorylation of Src at
Tyr416 increased by a factor of 3.8 ± 0.6. As seen for
17b-estradiol, inactivation of GPR30 by means of siRNA
clearly obviated the activation of the kinase Src by 4-hy-
droxytamoxifen (Fig. 3, upper panel, lane 5).
Next step analyzed in the signal transduction of GPR30
was the transactivation of the EGF-R. In the course of
GPR30 signaling, certain membrane bound matrix metal-
loproteases are activated and release EGF from the extra-
cellular matrix. The degree of transactivation of the
EGF-receptor was determined by detecting the amount of
EGF-receptor phosphorylated at Tyr1173 on western blots.
Phosphorylation of the EGF-receptor slightly increased
after 10 min stimulation of MDA-MB-435 cells with 10-9
M 17b-estradiol (Fig. 3, panel 3, lane 2). In cells trans-
fected with siRNA against GPR30 (?si), the phosphory-
lation status of the EGF-receptor was much lower than in
cells transfected with non-specific siRNA (-si; Fig. 3,
panel 3, lane 3).
Treatment of the triple-negative breast cancer cells with
10-6 M 4-hydroxytamoxifen stimulated the phosphoryla-
tion of the EGF-receptor more strongly than it was
observed after treatment with 17b-estradiol (Fig. 3, panel
3, lane 4). Phosphorylation of EGF-receptor by 4-hy-
droxytamoxifen was almost completely abolished in cells
transfected with siRNA directed against GPR30 (?si;
Fig. 3, panel 3, lane 5).
The analysis of GPR30 signaling in the cell line
HCC1806 showed similar consequences of the knock-
down of GPR30 mRNA (data not shown).
Expression of c-fos protooncogene in response to
17b-estradiol and 4-hydroxytamoxifen
Expression of c-fos is a prerequisite of proliferation.
Therefore, c-fos expression was analyzed in two triple-
negative cell lines after treatment with either 17b-estradiol
or 4-hydroxytamoxifen. Upregulation of c-fos expression
by these two compounds in cells transfected with control
siRNA (-si) was compared with c-fos expression of cells
pretreated for 7 days with siRNA against GPR30 (?si).
In control cells of the cell line MDA-MB-435 (-si),
expression of c-fos clearly increased after 30 min stimu-
lation with 10-9 M 17b-estradiol (1.5-fold) as well as 10-6
M 4-hydroxytamoxifen (3.1-fold, p \ 0.001) (Fig. 4a).
Inactivation of GPR30 led to an almost complete inhibition
of c-fos induction (Fig. 4a, lanes 5 and 6).
In HCC1806 cells, 17b-estradiol stimulated c-fos
expression about 1.8-fold (p \ 0.01) and 4-hydroxytam-
oxifen led to an about twofold increase (p \ 0.01) of c-fos
expression (Fig. 4b). Suppression of GPR30 expression
using siRNA blocked the induction of c-fos by both com-
pounds in HCC1806 cells similar to the effects observed in
MDA-MB-435 cells (Fig. 4b, lanes 5 and 6).
Discussion
The clinical outcome for patients with triple-negative
breast cancer is still poor, despite intensive chemotherapy
using cytotoxic drugs like platinum compounds. A search
for more specific, targeted therapeutic options has been
performed in recent years. In particular, PARP inhibitors
were applied, taking advantage of a disturbed DNA-repair
due to frequent BRCA1-mutations present in triple-nega-
tive breast cancer [4, 5]. Other investigators have chosen
the frequently observed overexpression of the EGF-recep-
tor as target using EGF-R antibody Cetuximab for a tai-
lored therapy [3].
In the present study, we investigated the possible role of
the GPR30, in the growth stimulation of triple-negative
breast cancer cells. Immunohistochemical staining of
Fig. 3 Disruption of signal transduction of GPR30 in the siRNA-
treated cells of the triple-negative breast cancer cell lines MDA-MB-
435. Cells transfected with siRNA (?si) and control cells (-si) were
stimulated for 10 min with either 10-9 M 17b-estradiol or 10-6 M
4-hydroxytamoxifen. Cells were lysed, proteins separated in a
polyacrylamide gel, blotted onto a PVDF-membrane, and the
indicated proteins were sequentially detected with antibodies against
phospho-src (panel 1), total-src (panel 2), phospho-EGF-receptor
(panel 3), total EGF-receptor (panel 4), and actin, as housekeeping
gene (panel 7). Representative results of three independent
preparations
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sections from triple-negative breast tumors revealed that
almost all tumors were strongly positive for GPR30
(unpublished results). GPR30 was also found to be strongly
expressed in the two triple-negative cell lines under
investigation. Therefore, GPR30 expression is a feature
frequently occurring in triple-negative breast cancer that
might be used for targeted therapy.
Filardo et al. [11] intensively examined the role of
GPR30 in response to 17b-estradiol and unraveled the
signaling pathway downstream of this receptor. Ligands
binding to GPR30 induce the dissociation of the hetero-
trimeric G-proteins. The bc-subunit activates the tyrosine
kinase Src. Subsequently, EGF-receptor is autophosphor-
ylated at tyrosine1173 initiating the ras-MAP-kinase sig-
naling, finally inducing proliferation of estrogen-stimulated
cells independent of ERa [8, 9]. Most experiments eluci-
dating the signaling pathways of GPR30 were performed
with the breast cancer cell line SK-Br3 lacking expression
of ERa and ERb. However, this SK-Br3 cell line does not
represent a triple-negative breast cancer cell line, as SK-
Br3 cells overexpress Her2, whereas triple-negative breast
cancer cells lack overexpression of human EGF-receptor 2
(Her-2) [18].
In contrast, many triple-negative breast tumors overex-
press the EGF-receptor (Her-1) [19]. EGF is able to induce
the expression of GPR30 [20]. 17b-Estradiol activates the
cytosolic kinase Src via GPR30 and Src activates matrix
metalloproteases that release EGF from extracellular
matrix. The subsequent induction of GPR30 expression
leads to a positive feedback loop that boosts the induction
of proliferation by 17b-estradiol in triple-negative breast
tumors.
In this report, we present evidence that in the triple-
negative breast cancer cells studied, all necessary steps
of the GPR30 signaling are activated in response to
17b-estradiol and 4-hydroxytamoxifen. Src phosphoryla-
tion is increased in both cell lines and EGF-receptor is
phosphorylated at Tyr1173 after stimulation with both
estrogenic compounds. Both kinases are more strongly
activated by 4-hydroxytamoxifen than by 17b-estradiol.
The activation of these kinases was completely prevented
in the triple-negative cell lines by knock-down of GPR30.
Some controversy exists about the nature of the estrogen
receptor that is responsible for the rapid non-genomic
effects of 17b-estradiol. Whereas some authors concluded
that the activation of Src kinase, EGF-receptor, and the
MAP-kinase Erk1/2 in breast cancer cells lacking ERa is
elicited by GPR30 [11, 12], other authors predominantly
hypothesize the presence of a truncated ERa that localizes
at the membrane supported by the scaffolding protein
caveolin [10].
Opposite to this, the results of our experiments
provide further evidence that the non-genomic effects of
17b-estradiol, like activation of c-Src, phosphorylation of
the EGF-receptor, and increased expression of c-fos, are
dependent on the presence of GPR30. As we describe in
this report, all these non-genomic effects of 17b-estradiol
are detectable in the two triple-negative breast cancer cell
lines and inactivation of GPR30 by means of siRNA pre-
vent the activation of all pathways described above.
Fig. 4 Prevention of c-fos expression by the knock-down of GPR30.
Triple-negative breast cancer cell lines, a MDA-MB-435 and
b HCC1806, transfected with non-specific siRNA (control) or with
GPR30siRNA were stimulated for 30 min either with 10-9 M
17b-estradiol or 10-6 M 4-hydroxytamoxifen. mRNA was extracted,
transcribed into cDNA, and amplified by PCR using primers specific
for c-fos. L7, a ribosomal housekeeping gene, was amplified to prove
the presence of equal amounts of RNA in each PCR reaction of the
respective cell line. Representative results of three separate experi-
ments. (a) p \ 0.001 versus control, (b) p \ 0.01 versus control,
(c) p \ 0.001 versus TAM, -si, (d) p \ 0.01 versus E2, -si,
(e) p \ 0.01 versus TAM, -si
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Therefore, this report proves without doubt that GPR30
mediates the non-genomic effects of 17b-estradiol.
From the clinical point of view, the results presented in
this report highlight GPR30 as an important new target for
a more specific therapy of triple-negative breast cancer.
There have already been described some compounds
that specifically inhibit GPR30. Estriol binds to GPR30 and
inhibits GPR30 signaling weakly as shown for the upreg-
ulation of c-fos expression [21]. A substituted dihydro-
quinoline, G15, was identified that binds to GPR30 with
an affinity of 20 nM. G15 was able to effectively block
calcium mobilization by 17b-estradiol in the GPR30
expressing breast cancer cells SKBr3 [22]. Despite this,
there is still a need to search for more effective inhibitors
of GPR30 possessing a higher affinity and good bioavail-
ability, before a therapy of triple-negative breast cancer
targeting GPR30 may enter clinical trials.
Acknowledgments We thank Sonja Blume, Renate Dietrich, and
Matthias La¨sche for excellent technical assistance.
Conflict of Interest The authors declare that they have no conflict
of interest.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
References
1. Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, Buyse
M, Baum M, Buzdar A, Colleoni M, Coombes C, Snowdon C,
Gnant M, Jakesz R, Kaufmann M, Boccardo F, Godwin J, Davies
C, Peto R (2010) Meta-analysis of breast cancer outcomes in
adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin
Oncol 28:509–518
2. Nofech-Mozes S, Trudeau M, Kahn HK, Dent R, Rawlinson E,
Sun P, Narod SA, Hanna WM (2009) Patterns of recurrence in the
basal and non-basal subtypes of triple-negative breast cancers.
Breast Cancer Res Treat 118:131–137
3. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F,
Ollila DW, Sartor CI, Graham ML, Perou CM (2007) The triple
negative paradox: primary tumor chemosensitivity of breast
cancer subtypes. Clin Cancer Res 13:2329–2334
4. Anders CK, Winer EP, Ford JM, Dent R, Silver DP, Sledge GW,
Carey LA (2010) Poly(ADP-ribose) polymerase inhibition:
‘‘targeted’’ therapy for triple-negative breast cancer. Clin Cancer
Res 16:4702–4710
5. Telli ML, Ford JM (2010) PARP inhibitors in breast cancer. Clin
Adv Hematol Oncol 8:629–635
6. Tsai EM, Wang SC, Lee JN, Hung MC (2001) Akt activation by
estrogen in estrogen receptor-negative breast cancer cells. Cancer
Res 61:8390–8392
7. Aronica SM, Kraus WL, Katzenellenbogen BS (1994) Estrogen
action via the cAMP signaling pathway: stimulation of adenylate
cyclase and cAMP-regulated gene transcription. Proc Natl Acad
Sci USA 91:8517–8521
8. Migliaccio A, Di Domenico M, Castoria G, de Falco A, Bon-
tempo P, Nola E, Auricchio F (1996) Tyrosine kinase/p21ras/
MAP-kinase pathway activation by estradiol-receptor complex in
MCF-7 cells. EMBO J 15:1292–1300
9. Visram H, Greer PA (2006) 17Beta-estradiol and tamoxifen
stimulate rapid and transient ERK activation in MCF-7 cells via
distinct signaling mechanisms. Cancer Biol Ther 5:1677–1682
10. Razandi M, Oh P, Pedram A, Schnitzer J, Levin ER (2002) ERs
associate with and regulate the production of caveolin: implica-
tions for signaling and cellular actions. Mol Endocrinol 16:
100–115
11. Filardo EJ, Quinn JA, Bland KI, Frackelton AR Jr (2000)
Estrogen-induced activation of Erk-1 and Erk-2 requires the G
protein-coupled receptor homolog, GPR30, and occurs via trans-
activation of the epidermal growth factor receptor through release
of HB-EGF. Mol Endocrinol 14:1649–1660
12. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER
(2005) A transmembrane intracellular estrogen receptor mediates
rapid cell signaling. Science 307:1625–1630
13. Luttrell LM, Daaka Y, Lefkowitz RJ (1999) Regulation of tyro-
sine kinase cascades by G-protein-coupled receptors. Curr Opin
Cell Biol 11:177–183
14. Maggiolini M, Vivacqua A, Fasanella G, Recchia AG, Sisci D,
Pezzi V, Montanaro D, Musti AM, Picard D, Ando S (2004) The
G protein-coupled receptor GPR30 mediates c-fos up-regulation
by 17beta-estradiol and phytoestrogens in breast cancer cells.
J Biol Chem 279:27008–27016
15. Chen JQ, Russo J (2009) ERalpha-negative and triple negative
breast cancer: molecular features and potential therapeutic
approaches. Biochim Biophys Acta 1796:162–175
16. Girgert R, Bartsch C, Hill SM, Kreienberg R, Hanf V (2003)
Tracking the elusive antiestrogenic effect of melatonin: a new
methodological approach. Neuroendocrinol Lett 24:440–444
17. Stanley ER, Palmer RE, Sohn U (1977) Development of methods
for the quantitative in vitro analysis of androgen-dependent and
autonomous Shionogi carcinoma 115 cells. Cell 10:35–44
18. Huang X, Gao L, Wang S, McManaman JL, Thor AD, Yang X,
Esteva FJ, Liu B (2010) Heterotrimerization of the growth factor
receptors erbB2, erbB3, and insulin-like growth factor-I receptor
in breast cancer cells resistant to herceptin. Cancer Res
70:1204–1214
19. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z,
Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen
LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM
(2004) Immunohistochemical and clinical characterization of the
basal-like subtype of invasive breast carcinoma. Clin Cancer Res
10:5367–5374
20. Albanito L, Sisci D, Aquila S, Brunelli E, Vivacqua A, Madeo A,
Lappano R, Pandey DP, Picard D, Mauro L, Ando S, Maggiolini
M (2008) Epidermal growth factor induces G protein-coupled
receptor 30 expression in estrogen receptor-negative breast can-
cer cells. Endocrinology 149:3799–3808
21. Lappano R, Rosano C, De Marco P, De Francesco EM, Pezzi V,
Maggiolini M (2010) Estriol acts as a GPR30 antagonist in
estrogen receptor-negative breast cancer cells. Mol Cell Endo-
crinol 320:162–170
22. Dennis MK, Burai R, Ramesh C, Petrie WK, Alcon SN, Nayak
TK, Bologa CG, Leitao A, Brailoiu E, Deliu E, Dun NJ, Sklar
LA, Hathaway HJ, Arterburn JB, Oprea TI, Prossnitz ER (2009)
In vivo effects of a GPR30 antagonist. Nat Chem Biol 5:421–427
Breast Cancer Res Treat (2012) 134:199–205 205
123
